Selected Targets. Subject to the terms of this Agreement and any applicable [**], during the Research Program Term, BMS hereby grants to Lexicon and its Affiliates, within the Territory, (a) a non-exclusive right and license (without any right to sublicense, except as set forth below) under BMS's rights in the BMS Background Materials and the BMS Background Technology and (b) a co-exclusive right and license (without any right to sublicense, except as set forth below) under BMS's rights in the Program Intellectual Property to (i) identify and validate Selected Targets (other than Selected Targets that have become BMS Inactive Selected Targets, Lexicon Inactive Selected Targets, BMS Targets or Lexicon Targets) for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field, (ii) identify Small Molecule Compounds that are active against such Selected Targets through the use of such Selected Targets and (iii) undertake preclinical research and evaluation of Program Compounds, in each case in the conduct of the Research Program. Such right and license shall include the right to grant sublicenses to Third Parties that are approved by the Joint Management Committee.
Selected Targets. During the applicable Selection Period, Xxxxx shall have the right to select from the Reserved Targets:
Selected Targets. From time to time during the term of this Agreement, Sanwa may notify Telik of a Sanwa Target, or pursuant to the terms of Section 1.5, a Third Party Target, (collectively "Selected Target") which Sanwa wishes to use in screening compounds submitted by Telik; provided, however, Sanwa may not submit more than [*] Selected Targets (not including Excluded Targets) during the term of this Agreement as set forth in Section 7.1 hereof.
Selected Targets. For clarity, (1) where the reason for rejection is provided under Clause 3.1.5(a)(ii), Clause 3.1.4(b) will not apply to such a rejected Non-Validated Target; provided, that, if Lilly requests that Immunocore notify Lilly if such Non-Validated Target becomes available for validation, Immunocore shall so notify Lilly promptly following such Non-Validated Target becoming available for validation; and (2) where Lilly elects to continue with a Non-Validated Target given the communication of restrictions by Immunocore under (B) above, any license or rights granted in relation to such Non-Validated Target will be subject to the communicated, written, restrictions.
Selected Targets. During the Selection Term, GSK shall have the right to select, from the Available Targets, up to three (3) Targets at the same time at any given point in time (each, a “Selected Target”), each of which shall be the focus of activities under a Research Plan. For clarity, at no one point in time shall more than three (3) Targets be designated as Selected Targets. While the Parties shall discuss the characteristics and relative scientific merits of each Available Target that is of potential interest, GSK shall have the final decision of whether and which Available Targets to select to be Selected Targets under this Agreement.
Selected Targets. During the Research Term, subject to the terms of this Section 2.8, Juno shall have the right to select Targets to be Selected Targets by providing written notice to Fate and payment of the payment set forth in Section 5.4. Upon such written notice and payment for a given Target, such Target shall be a “Selected Target.” There shall not be any limit on the number of Selected Targets (other than the requirement that such Target was on the Target List); provided, however, that Juno shall only have the right to select a Target as a Selected Target if [***]. For clarification (i) if Juno [***] then each such antigen or protein shall be selected by Juno as a Selected Target in accordance with this Section 2.8 in connection with [***], and (ii) [***]. For the avoidance of doubt, Juno may modify an existing Modulated Product incorporating as an active ingredient an Engineered T-Cell directed against such Selected Target(s) by [***].
Selected Targets. Prior to offering any Third Party the opportunity to acquire a license to develop and commercialize a [ * ] identified by Exelixis pursuant to its rights under [ * ]or a [ * ], Exelixis shall provide P&U with the opportunity to consider whether it wishes to acquire such a license. P&U shall have [ * ] following such offer in which to inform Exelixis in writing that it is interested in acquiring such a license. Thereafter, the Parties shall negotiate in good faith for [ * ] to reach agreement on the terms of a license agreement which shall be set forth in either an executed license agreement or an executed legally binding heads of agreement. If P&U fails to notify Exelixis of its interest or the Parties fail to execute a license agreement within the applicable period, then P&U shall have no rights with respect to such use of said Selected Target and Exelixis shall have unrestricted rights to pursue (without compensation to P&U) these applications of the Selected Target, including, but not limited to, conducting Independent Research on said Selected Target and developing or commercializing products incorporating, based upon or identified using said Selected Target. The foregoing [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Selected Targets. BMS shall make a milestone payment to Exelixis of [ * ] after BMS' selection, pursuant to Section 3.3 or 5.5(e), of (i) the sixth BMS Selected Target and (ii) each subsequent sixth BMS Selected Target (wherein the counting of BMS Selected Targets restarts at one after each group of six). Upon the last JSC meeting after the end of the Research Term, BMS shall make a milestone payment to Exelixis equal to [ * ].
Selected Targets. Subject to the terms of this Agreement and any applicable Pre‑existing Obligations, during the Research Program Term, BMS hereby grants to Lexicon and its Affiliates, within the Territory, (a) a non-exclusive right and license (without any right to sublicense, except as set forth below) under BMS’s rights in the BMS Background Materials and the BMS Background Technology and (b) a co-exclusive right and license (without any right to sublicense, except as set forth below) under BMS’s rights in the Program Intellectual Property to (i) identify and validate Selected Targets (other than Selected Targets that have become BMS Inactive Selected Targets, Lexicon Inactive Selected Targets, BMS Targets or Lexicon Targets) for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field, (ii) identify Small Molecule Compounds that are active against such Selected Targets through the use of such Selected Targets and (iii) undertake preclinical research and evaluation of Program Compounds, in each case in the conduct of the Research Program. Such right and license shall include the right to grant sublicenses to Third Parties that are approved by the Joint Management Committee.
Selected Targets. 11 4.3.1 Selection...................................................11 4.3.2 Validated Assay Development.................................11 4.3.3 Validated Assay Transfer and Implementation.................11 ARTICLE 5 COMPOUND SCREENING; ACTIVE CUBIST COMPOUNDS......................12 5.1 Screening of Compounds...............................................12 5.1.1 Third Party Compounds.......................................12 5.2 Identification of Active Cubist Compounds............................12 5.2.1 Active Cubist Compound......................................12 5.2.2 Novartis Compound/Active Cubist Compound Derivative.........13 ARTICLE 6
